ERBB2 and gastric cancer: A combination of MET and HER2 targeted therapies exerted a significant synergism in gastric cancer PDX models, suggesting this combination strategy may be a potential therapeutic option for some gastric cancer patients and warrants a further investigation in clinical studies.